Kymera Therapeutics (KYMR) vs Bio-Techne (TECH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Kymera Therapeutics (KYMR) has outperformed Bio-Techne (TECH) over the past year, gaining 89.3% versus a gain of 22.5%. Over five years, KYMR leads with a +89.4% price change compared with -41.7% for TECH. Bio-Techne is the larger company by market cap ($11.37 billion vs $8.91 billion), about 1.3 times the size.
Bio-Techne pays a dividend yielding 0.44%, while Kymera Therapeutics does not currently pay one. Bio-Techne converts more of its revenue into profit, with a net margin of 15.0% versus -794.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KYMR | TECH |
|---|---|---|
| Share price | $108.35 | $72.53 |
| Market cap | $8.91B | $11.37B |
| 1-day change | +2.24% | +0.14% |
| YTD return | +38.45% | +23.33% |
| 1-year return | +89.26% | +22.54% |
| 5-year return | +89.42% | -41.75% |
| P/E ratio (TTM) | — | 62.53 |
| Forward P/E | — | 31.36 |
| EPS (TTM) | $-3.33 | $1.16 |
| Dividend yield | 0.00% | 0.44% |
| Annual dividend | $0.00 | $0.32 |
| Revenue (latest FY) | $39.21M | $1.22B |
| Revenue growth (YoY) | -16.70% | -0.38% |
| Net income (latest FY) | $-311.35M | $181.86M |
| Gross margin | 0.00% | 65.77% |
| Operating margin | -891.07% | 20.73% |
| Net margin | -794.04% | 14.97% |
| 52-week high | $130.05 | $72.69 |
| 52-week low | $55.26 | $43.20 |
| Distance from 52-week high | -16.69% | -0.22% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +28.58% | -2.80% |
| Average volume | 690.98K | 3.08M |
| Shares outstanding | 82.26M | 156.82M |
| Employees | 273 | 3,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KYMR has outperformed TECH by 66.7 percentage points over the past year.
- Bio-Techne is more profitable, keeping 15.0 cents of every revenue dollar as net income versus -794.0 cents for Kymera Therapeutics.
- Bio-Techne grew revenue faster in its latest fiscal year (-0.38% vs -16.70%).
About Kymera Therapeutics
KYMR stock →Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis; and cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential, including in breast cancer and other solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 273 employees
About Bio-Techne
TECH stock →Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 3,000 employees
KYMR vs TECH FAQ
Which is bigger, Kymera Therapeutics or Bio-Techne?
Bio-Techne (TECH) is larger, with a market capitalization of $11.37B compared with $8.91B for Kymera Therapeutics (KYMR).
Which stock has performed better over the past year, KYMR or TECH?
KYMR returned +89.26% over the past 12 months, compared with +22.54% for TECH (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Kymera Therapeutics or Bio-Techne?
Bio-Techne pays a dividend yielding 0.44%, while Kymera Therapeutics does not currently pay a regular dividend.
Are Kymera Therapeutics and Bio-Techne in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.